Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 203 for melanoma

Edit search filters
  1. IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

    Jacksonville, FL

  2. Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

    Rochester, MN

  3. A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

    Rochester, MN

  5. MC1R-targeted Alpha-particle Monotherapy And Combination Therapy Trial With Nivolumab In Adults With Advanced Melanoma

    Rochester, MN, Jacksonville, FL

  6. Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

    Rochester, MN

  7. MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

    Rochester, MN

  8. Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

    Rochester, MN

  9. Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

    Jacksonville, FL

.

Mayo Clinic Footer